Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/2003
06/05/2003WO2003045324A2 14-methyl-epothilones
06/05/2003WO2003045318A2 Manipulation of cytokine levels using cd83 gene products
06/05/2003WO2003045313A2 2-aminoquinoline compounds
06/05/2003WO2003045312A2 Biosynthetic gene cluster for the maytansinoid antitumor agent ansamitocin
06/05/2003WO2003045307A2 Pharmaceutical formulations comprising indolinone derivatives
06/05/2003WO2003045230A2 Novel compositions and methods for cancer
06/05/2003WO2003045229A2 Methods and compositions for treating cancer
06/05/2003WO2003045227A2 Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness
06/05/2003WO2003035043A3 Pharmaceutical formulation comprising more than 15% tamoxifen
06/05/2003WO2003008430A3 Porphyrin derivatives for photodynamic therapy
06/05/2003WO2003004526A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines
06/05/2003WO2003002764A3 Screening method for identifying cancer therapy-relevant compounds
06/05/2003WO2003000296A3 Treatment and diagnostic of b cell chronic lymphocytic leukaemia
06/05/2003WO2002102306A3 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
06/05/2003WO2002085843A3 Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
06/05/2003WO2002074924A3 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof
06/05/2003WO2002069949A3 Combination therapy for reduction of toxycity of chemotherapeutic agents
06/05/2003WO2002068548A3 Use of erss-selective ligands for regulating fertility and compounds useful therefore
06/05/2003WO2002062841A3 Secreted proteins
06/05/2003WO2002060932A3 A serpin in bifidobacteria
06/05/2003WO2002060864A9 Process of obtaining compositions of stable lutein and lutein derivatives
06/05/2003WO2002060485A3 Use of immunoregulatory antibodies in the treatment of neoplastic disorders
06/05/2003WO2002046230A3 G-protein coupled receptors
06/05/2003WO2002042330A3 Cystoskeleton-associated proteins
06/05/2003WO2002036075A3 Small molecule compositions for binding to hsp90
06/05/2003US20030106082 Transgenic stem cells, formed by dissociating blastomeres, are cultured, impregnated within surrogate; animals models; gene therapy
06/05/2003US20030105333 RXR activating molecules
06/05/2003US20030105324 Camptothecin analogs and methods of preparation thereof
06/05/2003US20030105311 Oligonucleotides having A-DNA form and B-DNA form conformational geometry
06/05/2003US20030105300 Carbocyanine dyes/bioconjugates; optical tomography; fluorescence endoscopy; treating atherosclerotic plaques and blood clots; laser detection of metastasis
06/05/2003US20030105299 Carbocyanine dyes for tandem, photodiagnostic and therapeutic applications
06/05/2003US20030105293 Human circulating cytokine cc-1
06/05/2003US20030105165 Gap junctions and EDHF
06/05/2003US20030105151 Anticancer agents; antiinflammatory agents; autoimmune diseases; rheumatic diseases
06/05/2003US20030105150 Method of treating of demyelinating diseases or conditions
06/05/2003US20030105148 Selective estrogen receptor modulators
06/05/2003US20030105129 Chemical compounds
06/05/2003US20030105122 Compounds for enhancing chemotherapy
06/05/2003US20030105118 Tricyclic quinazolinediones
06/05/2003US20030105116 Fused tri-heterocyclic compounds
06/05/2003US20030105115 For therapy of cancer, diseases mediated by kinase, osteoporosis
06/05/2003US20030105114 Methods of treatment and kits comprising a growth hormone secretagogue
06/05/2003US20030105110 Novel compounds
06/05/2003US20030105109 New campothecin analogue compounds
06/05/2003US20030105107 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
06/05/2003US20030105104 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
06/05/2003US20030105102 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity
06/05/2003US20030105098 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
06/05/2003US20030105095 4'-Methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
06/05/2003US20030105090 For therapy of cancer, diabetes
06/05/2003US20030105088 Thiol-based NAALADase inhibitors
06/05/2003US20030105087 New polycyclic azaindole compounds
06/05/2003US20030105078 Diphenyl derivatives
06/05/2003US20030105075 Hymenialdisine or derivatives thereof in the manufacture of medicaments
06/05/2003US20030105070 Porphyrins with enhanced multi-photon absorption cross-sections for photodynamic therapy
06/05/2003US20030105069 Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
06/05/2003US20030105052 Oligoribonucleotide derivatives for specific inhibition of gene expression
06/05/2003US20030105025 Tri-and tetrapeptides having antiangiogenic activity
06/05/2003US20030104992 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
06/05/2003US20030104977 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
06/05/2003US20030104976 Analgesic methods using endothelin receptor ligands
06/05/2003US20030104975 Useful for identification of compounds that induce or inhibit the recruitment of the p160 family cofactors, especially TIF-2 and/ or SRCs cofactors (Translation initiation factor-2 and steroid receptor cofactors)
06/05/2003US20030104974 Dual inhibitorsof PDE 7 and PDE 4
06/05/2003US20030104627 Method and an apparatus for generating shockwave, a method and an apparatus for accelerating particles, an apparatus for delivering drugs, and a method and an apparatus for delivering DNA
06/05/2003US20030104625 Novel oncolytic adenoviral vectors
06/05/2003US20030104624 Novel vector constructs
06/05/2003US20030104570 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
06/05/2003US20030104569 Proteins suppressing proliferation of lympho-hematopoietic cells
06/05/2003US20030104532 Neuroprotectants; angoigenesis inhibitors; transcription factors
06/05/2003US20030104530 Inhibiting competetive binding; maintenance of organelle equilibrium; drug resistance
06/05/2003US20030104528 Lymphocytes; transcription factors; interferons
06/05/2003US20030104516 Protein kinase npk-110
06/05/2003US20030104500 Enzymatic assays for screening anti-cancer agents
06/05/2003US20030104478 Screening modulators of g-protein activity: for use in treatment of nervous system disorders
06/05/2003US20030104455 Methods and compositions for treating urological disorders using 313, 333, 5464, 18817 or 33524
06/05/2003US20030104419 Method of classifying a thyroid carcinoma using differential gene expression
06/05/2003US20030104400 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of infammatory, immunol;ogical and nervous system disorders
06/05/2003US20030104377 Tenascin-C nucleic acid ligands
06/05/2003US20030104089 Induced by urethane or by (((4-N-methyl-N-nitrosoamino)-1-(3-pyridyl)-1-butanone)))
06/05/2003US20030104053 Drug dispersed in a solid unitary matrix formed of poly(ethylene oxide) and hydroxypropyl methylcellulose.
06/05/2003US20030104005 Physiologically active compositions based upon active ingredients of basidiomycotina and araliaceae
06/05/2003US20030103995 Detection and therapy of vulnerable plaque with photodynamic compounds
06/05/2003US20030103986 TACI-immunoglobulin fusion proteins
06/05/2003US20030103982 Therapeutic using a bispecific antibody
06/05/2003US20030103978 Antibodies and antigen binding domains used to prevent or treat conditions relating to loss of bone mass and bone disorders; nucleic acid encoding antibodies and antigen binding domains
06/05/2003US20030103974 Administering an antibodies or enzyme inhibitor of prothrombinase; therapeutic treatment of bacterial and viral infections, allograft and xenograft rejection, cancer, glomerulonephritis, gastrointestinal disorders and fetal loss
06/05/2003US20030103973 Method for reducing tumor growth with VEGF antagonists combined with radiation and chemotherapy
06/05/2003US20030103968 Use of alpha specific antibody BIBH1 in the treatment of cancer
06/05/2003US20030103957 Comprises adenosine-diphosphate transferase activity; drug delivery; for suppressing inhibition of neuronal axon growth
06/05/2003US20030103937 Comprises interleukins for enhancing engraphment of bone marrow during transplantation; for treating allergies and blood disorders
06/05/2003US20030103896 Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents
06/05/2003CA2486924A1 Use of t-cell immune response cdna 7 (tirc7) for modulation of angiogenesis and/or neovascularization
06/05/2003CA2468878A1 Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation
06/05/2003CA2468718A1 Fusion proteins containing tlp peptides
06/05/2003CA2468548A1 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
06/05/2003CA2468316A1 Novel compositions and methods for cancer
06/05/2003CA2468312A1 Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness
06/05/2003CA2468253A1 Process for coating a surface of a stent
06/05/2003CA2468187A1 Peptides with growth inhibitory action
06/05/2003CA2468184A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
1 ... 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 ... 2211